drugset
drugset / Trial / NCT04352114

A Study of LY3461767 in Healthy Participants

NCT04352114 ↗

Phase 1 Completed 48 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindBasic science

Summary

The main purpose of this study in healthy participants is to learn more about the safety of LY3461767 and any side effects that might be associated with it. The study will also measure how much LY3461767 gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last about 11 weeks, including screening.

Timeline

Start
2020-06-15
Primary completion
2021-01-13
Completion
2021-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject RUGECITIDE Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.